Drugs / bone marrow mononuclear cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02525432 | Nov 2016 → Jul 2024 | traumatic brain injury | The University of Texas Health Science Center, Houston | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bone marrow mononuclear cells | “intravenous infusion of autologous bone marrow mononuclear cells (BMMNC)” NCT02525432 ↗ |
| Known as | BMMNC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02525432 ↗ |
| Modality | Cell therapy | “autologous stem cell infusion” NCT02525432 ↗ |
| Route | Intravenous | “IV infusion of autologous bone marrow mononuclear cells” NCT02525432 ↗ |